Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.

ABSTRACT:

Objectives

This study sought to examine the efficacy of empiric antiarrhythmic drugs in a rigorously characterized cohort of arrhythmogenic right ventricular cardiomyopathy (ARVC) patients.

Background

Antiarrhythmic drugs are important in protecting against ventricular arrhythmias in ARVC, but no studies have provided data in a group rigorously screened for the disease.

Methods

Antiarrhythmic medicines were examined in all subjects with implantable cardioverter-defibrillators (ICDs) enrolled in the North American ARVC Registry. A Cox proportional hazards model was used to account for time on each drug, and a hierarchical analysis was performed for repeated measures within individuals.

Results

Ninety-five patients were studied, with a mean follow-up of 480 +/- 3

SUBMITTER: Marcus GM 

PROVIDER: S-EPMC2748738 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature